The Oligonucleotide Therapeutics Society aims to foster academia and industry-based research and development of oligonucleotide therapeutics. The society envisions a new era of oligonucleotide drugs that vastly impacts therapeutic modalities, much like antibodies have revolutionized human therapeutics.
The Mary Ann Liebert, Inc. publishers Young Investigator Award, sponsored by the Oligonucleotide Therapeutics Society (OTS), supports outstanding achievements in the field of oligonucleotide therapeutics. It is targeted at professionals who have received their doctoral degree within the past fifteen years, highlighting contributions that have the potential to advance the field. The grant provides a $2,000 USD award, complimentary registration to the OTS Annual Meeting, an opportunity to formally receive the award, and a speaking slot at the meeting, emphasizing the significance of fostering new talent and encouraging groundbreaking research in oligonucleotide therapeutics.